Read by QxMD icon Read


Jean-Yves Blay
Surgery (+ radiation therapy in selected cases) is standard treatment for adult-type localized soft tissue sarcoma (STS). Accumulating randomized clinical evidence also supports adjuvant chemotherapy as a treatment option, although this remains contentious. Doxorubicin (± ifosfamide) is the standard first-line systemic treatment for advanced STS; however, newer chemotherapeutic agents may improve outcomes achieved with single-agent doxorubicin. In a Phase II study, adding olaratumab to doxorubicin markedly improved overall survival...
May 2018: Future Oncology
Shunichiro Miki, Shoji Imamichi, Hiroaki Fujimori, Arata Tomiyama, Kenji Fujimoto, Kaishi Satomi, Yuko Matsushita, Sanae Matsuzaki, Masamichi Takahashi, Eiichi Ishikawa, Tetsuya Yamamoto, Akira Matsumura, Akitake Mukasa, Ryo Nishikawa, Kenkichi Masutomi, Yoshitaka Narita, Mitsuko Masutani, Koichi Ichimura
Glioblastoma is the most common and devastating type of malignant brain tumor. We recently found that eribulin suppresses glioma growth in vitro and in vivo and that eribulin is efficiently transferred into mouse brain tumors at a high concentration. Eribulin is a non-taxane microtubule inhibitor approved for breast cancer and liposarcoma. Cells arrested in M-phase by chemotherapeutic agents such as microtubule inhibitors are highly sensitive to radiation-induced DNA damage. Several recent case reports demonstrated the clinical benefits of eribulin combined with radiation therapy for metastatic brain tumors...
May 14, 2018: Cancer Science
Hisako Ono, Yoshihiro Sowa, Mano Horinaka, Yosuke Iizumi, Motoki Watanabe, Mie Morita, Emi Nishimoto, Tetsuya Taguchi, Toshiyuki Sakai
PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Therefore, there is an urgent need for a more effective treatment for the management of TNBC...
May 11, 2018: Breast Cancer Research and Treatment
(no author information available yet)
The CXCR4 antagonist balixafortide plus eribulin achieves responses in metastatic breast cancer.
May 4, 2018: Cancer Discovery
Eric S Schafer, Rachel E Rau, Stacey Berg, Xiaowei Liu, Charles G Minard, David D'Adamo, Rachael Scott, Larisa Reyderman, Gresel Martinez, Sandhya Devarajan, Joel M Reid, Elizabeth Fox, Brenda J Weigel, Susan M Blaney
BACKGROUND: Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose-limiting toxicities (DLTs), maximum tolerated or recommended phase 2 dose (MTD/RP2D), and pharmacokinetics (PK) of eribulin in children with refractory or recurrent solid (excluding central nervous system) tumors. METHODS: Eribulin was administered intravenously on days 1 and 8 in 21-day cycles...
May 2, 2018: Pediatric Blood & Cancer
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Tamami Morisaki, Hisakazu Fujita, Tsutomu Takashima, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: Several proteins involved in immune regulation and the relationship among these, the tumor microenvironment, and clinical outcomes of eribulin treatment were evaluated in advanced or metastatic breast cancer patients. PATIENTS AND METHODS: This retrospective cohort study comprised 52 eribulin-treated locally advanced or metastatic breast cancer patients. Cancer tissue samples were obtained before and after treatment in 10 patients. Immunohistochemistry was performed to determine programmed death (PD)-1, CD8, and forkhead box P3 (FOXP3) expression by stromal tumor-infiltrating lymphocytes, and PD-ligand (L1) and PD-L2 expression by cancer cells...
May 2018: Anticancer Research
Sonia Pernas, Miguel Martin, Peter A Kaufman, Marta Gil-Martin, Patricia Gomez Pardo, Sara Lopez-Tarruella, Luis Manso, Eva Ciruelos, Jose Alejandro Perez-Fidalgo, Cristina Hernando, Foluso O Ademuyiwa, Katherine Weilbaecher, Ingrid Mayer, Timothy J Pluard, Maria Martinez Garcia, Linda Vahdat, Jose Perez-Garcia, Achim Wach, Debra Barker, Samson Fung, Barbara Romagnoli, Javier Cortes
BACKGROUND: The C-X-C chemokine receptor type 4 (CXCR4)-stromal cell-derived factor-1α (SDF-1α) axis regulates function and trafficking of immune cells and the tumour microenvironment. CXCR4 antagonists have been shown to enhance the activity of different anticancer treatments in preclinical models. We assessed the safety, tolerability, pharmacokinetics, and preliminary phase 1 activity of the CXCR4 antagonist, balixafortide, in combination with eribulin chemotherapy in patients with heavily pretreated, relapsed metastatic breast cancer...
April 26, 2018: Lancet Oncology
T Fujimura, Y Sato, Y Kambayashi, K Tanita, A Tsukada, H Terui, A Hashimoto, S Aiba
Cutaneous angiosarcoma (CAS) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second-line therapy for advanced CAS remains contentious. This report describes three cases of advanced CAS treated with eribulin. In addition, we investigated serum sCD163, CXCL10 and CCL22 levels at several time points of tumour progression in these patients, revealing serum levels of sCD163 and CXCL10 as potential biomarkers for progression of CAS...
April 17, 2018: British Journal of Dermatology
Hirofumi Hasegawa, Shoichi Inokuchi, Dai Kitagawa, Kotaro Shibahara, Satoru Funahashi, Masayuki Kitamura
As the treatment for the liposarcoma, there is no effective chemotherapy and a surgical remedy is required. We present the case of a 64-year-old man who complained about difficulty in swallowing and discomfort of throat. Computed tomography revealed a large enhancing left sided retroperitoneal mass invading the retroperitoneal space and it was displaced to the right. Preoperative diagnosis was retroperitonealmal ignant tumor. Tumor excision were performed and around 4.0 kg tumor was removed though its size was too big and resected it separately...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Jana Rudá-Kučerová, D Mareček
Oceans cover a large part of our planet and they are a home for an enormous amount of species. A lot of them are still waiting to be discovered by man, much like the chemicals they synthesize. Marine pharmacology concerns itself with the study of these chemicals and their potential use in medicine. Origin in marine species is for the most part the only thing this large and diverse group of substances have in common, so the spectrum of possible applications is quite wide. Many of these substances have a unique mechanism of action, offering new therapeutic possibilities...
2018: Ceská a Slovenská Farmacie
Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu, Ming-Hung Hu, Yin-Che Lu, Wei-Jen Ou, Chin-Ho Kuo, Chieh-Han Chuang, Jung-Yu Kan, Fang-Ming Chen, Ming-Feng Hou
PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. RESULTS: The survival rate at 24 months was 57.2% (95% CI 51.0-62.9%) and the median time to treatment failure (TTF) was 3...
April 5, 2018: Breast Cancer Research and Treatment
Kazuma Iwamoto, Yasuhiro Fujisawa, Yousuke Ishitsuka, Hiroshi Maruyama, Yoshiyuki Nakamura, Naoko Okiyama, Rei Watanabe, Manabu Fujimoto
No abstract text is available yet for this article.
April 5, 2018: European Journal of Dermatology: EJD
Ruth Espinosa Aunión, Carmen Aida Ramírez Ruda, Carmela Rodríguez López, Teresa Curiel García, José Ángel García Saénz, Rafael López López
Skin localization occurs in about 25% of women with metastatic breast cancer and represents a major therapeutic challenge. Although clinical literature on response of cutaneous metastases to chemotherapy is scarce, good response to eribulin has been reported. Herein, the clinical courses of three women with skin lesions secondary to metastatic breast cancer are described. The first patient achieved a complete clinical response in skin metastases with good tolerability to fourth-line eribulin (progression-free survival [PFS]: 8...
March 2018: Future Oncology
Maria Lomas Garrido, Ana Jaén Morago, Pedro Sánchez Rovira, Paula Espinosa Olarte, Cristina Pernaut Sánchez, Luis Manso Sánchez
Although advancing age can greatly increase the complexities of treating metastatic breast cancer, chronological age alone is insufficient to determine the type or intensity of treatment. Older patients require an individualized approach that takes into account the patient's physical ability, social circumstances and mental capacity to tolerate treatment. This section features three older women treated with eribulin for metastatic breast cancer. In the first case, a 70-year-old woman maintained stable disease into her 34th month of treatment with third-line eribulin...
March 2018: Future Oncology
Daniel Acosta-Eyzaguirre, Isabel Calvo Plaza, Antonia Perelló Martorell, Elena Hernández Agudo, Laura García-Estévez
Hepatic impairment in breast cancer arises from metastatic spread of tumor cells to the liver and signals a poor prognosis. Systemic therapy is the mainstay of treatment. Three women with hepatic dysfunction secondary to breast cancer who were treated with eribulin are presented herein. In the first case, third-line eribulin at the time of acute liver failure due to metastases maintained response for up to 9 months with good tolerability. In the second case, a woman with secondary bone and liver disease had progression-free survival of 5 months to third-line eribulin and, upon rechallenge after a drug holiday, had almost four more months of stable disease...
March 2018: Future Oncology
Maria Del Mar Muñoz Sánchez, Maria Del Carmen Soriano Rodríguez, Maria José Molina Garrido, Ana López-González, Andrés García-Palomo, Laura López-González, Maria Yéssica Plata Fernández, Natalia Luque Caro, Pedro Sánchez Rovira
Numerous patient- and disease-related factors must be considered when deciding a treatment approach for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Hormone therapy (HT) is generally the first option in the absence of compelling reasons for chemotherapy (e.g., rapidly progressive visceral disease). After failure of first-choice HT, alternative HT options are usually attempted until hormone resistance occurs and chemotherapy becomes the treatment of choice...
March 2018: Future Oncology
Maria Isabel Gallegos Sancho, Raúl Márquez-Vázquez, Alfonso Sánchez-Muñoz
Triple-negative breast cancers are defined as tumors negative for estrogen receptors, progesterone receptors and human EGFR2. These tumors exhibit diverse biological behavior and have a poor prognosis; chemotherapy is the mainstay of treatment. The first case involves a young woman with cerebral and cerebellar metastases who achieved a persistent objective response to fourth-line eribulin. In the second case, a woman who became metastatic during adjuvant therapy with anthracyclines and taxanes, and was refractory to capecitabine + bevacizumab, achieved a partial response and local symptom improvement with eribulin + bevacizumab...
March 2018: Future Oncology
Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, Hiromi Ozawa, Yukie Fujimoto, Tomoko Higuchi, Arisa Nishimukai, Ayako Kira, Michiko Imamura, Yuichi Takatsuka, Yasuo Miyoshi
INTRODUCTION: Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC. PATIENTS AND METHODS: A total of 85 patients with MBC treated with eribulin (n = 59) or nab-paclitaxel (n = 26) were recruited...
March 8, 2018: Clinical Breast Cancer
Yasutaka Tono, Mikiya Ishihara, Yoshihiro Miyahara, Satoshi Tamaru, Hiroyasu Oda, Yoshiki Yamashita, Isao Tawara, Hiroaki Ikeda, Hiroshi Shiku, Toshiro Mizuno, Naoyuki Katayama
The standard treatment for advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is the triple combination of pertuzumab, trastuzumab and docetaxel, but some patients cannot tolerate taxane. To explore a non-taxane triple therapy, we conducted a feasibility study of pertuzumab, trastuzumab and eribulin mesylate (PTE) therapy for previously treated advanced HER2-positive breast cancer with analyses of quality of life and biomarkers. Ten patients were enrolled, two of whom had a history of docetaxel allergy...
March 13, 2018: Oncotarget
Kosei Kimura, Mitsuhiko Iwamoto, Satoru Tanaka, Daigo Yamamoto, Katsuhide Yoshidome, Hiroyuki Ogura, Risa Terasawa, Nobuki Matsunami, Yuko Takahashi, Toshikatsu Nitta, Takashi Morimoto, Hiroya Fujioka, Kanako Kawaguchi, Kazuhisa Uchiyama
PURPOSE: Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor receptor 2 (HER2)-negative MBC are still limited. Therefore, we conducted a phase II trial to investigate the efficacy and safety of eribulin for first- or second-line chemotherapy for HER2-negative MBC. MATERIALS AND METHODS: We performed a phase II, open-label, single-arm, multicenter study in Japan...
March 28, 2018: Cancer Chemotherapy and Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"